Geron Corporation (GERN) has been under a strong bear grip, hence the stock is down -17.37% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.56% in the past 1 week. The stock has risen by 2.73% in the past week indicating that the buyers are active at lower levels, but the stock is down -17.82% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 4.86% and the 50-Day Moving Average is 12.25%.The 200 Day SMA reached 23.44%
Geron Corporation (NASDAQ:GERN): After opening at $2.22, the stock dipped to an intraday low of $2.18 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $2.3 and the buying power remained strong till the end. The stock closed at $2.26 for the day, a gain of 2.73% for the day session. The total traded volume was 1,311,010. The stocks close on the previous trading day was $2.26.
Geron Corporation (GERN) : The consensus price target for Geron Corporation (GERN) is $4.38 for the short term with a standard deviation of $1.25. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $5, however, the pessimist price target for the company is $3.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.